ResearcherShiraz UniversityActive in the last 2 years

Fatemeh Moosavi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8078-1297; OpenAlex author ID A5032620524. Sources: OpenAlex.

Their work

Papers: 6 (first author 2, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 6

Sertraline Has Anticancer Effects and Enhances the Cytotoxicity of Chemotherapeutic Agents Against Pancreatic Cancer Cells. Co-author DOI 10.1002/ardp.70290 ↗
Olaparib has synergistic effects with DNA damaging agents in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbrc.2025.153080 ↗
Combination of chemotherapy and c-MET inhibitors has synergistic effects in c-MET overexpressing pancreatic cancer cells. Co-author DOI 10.1016/j.biochi.2024.12.006 ↗
Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence. Co-author DOI 10.1016/j.bbcan.2024.189185 ↗
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. First author DOI 10.1016/j.critrevonc.2022.103749 ↗
Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases incl… First author DOI 10.1038/s41598-021-83069-4 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Omidreza Firuzi · 6 shared papers, 2021–2026 · strength 1.66
Bahareh Hassani · 2 shared papers, 2024–2026 · strength 0.67
- Paper Olaparib has synergistic effects with DNA damaging agents in pancreatic ductal adenocarcinoma. DOI 10.1016/j.bbrc.2025.153080 ↗
- Paper Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence. DOI 10.1016/j.bbcan.2024.189185 ↗
Maedeh Shahrabi · 1 shared paper, 2026 · strength 0.36
- Paper Sertraline Has Anticancer Effects and Enhances the Cytotoxicity of Chemotherapeutic Agents Against Pancreatic Cancer Ce… DOI 10.1002/ardp.70290 ↗
Motahareh Mortazavi · 2 shared papers, 2021–2022 · strength 0.34
- Paper Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. DOI 10.1016/j.critrevonc.2022.103749 ↗
- Paper Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentiall… DOI 10.1038/s41598-021-83069-4 ↗
Elisa Giovannetti · 1 shared paper, 2022 · strength 0.20
- Paper Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. DOI 10.1016/j.critrevonc.2022.103749 ↗
Miriam Martini · 1 shared paper, 2022 · strength 0.20
- Paper Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. DOI 10.1016/j.critrevonc.2022.103749 ↗
Tahereh Damghani · 1 shared paper, 2021 · strength 0.13
- Paper Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentiall… DOI 10.1038/s41598-021-83069-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.